Oligonucleotide (Antisense oligonucleotide) · Gene silencing: huntingtin (HTT) · developed by Wave Life Sciences
WVE-120101 is a stereopure antisense oligonucleotide that reduces huntingtin protein production. It is studied in Huntington's disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03225833 | Phase 1/2 | Huntington's Disease | Terminated | WVE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Huntington's Disease
Updated Oct 3, 2026. Something wrong or missing? Report it on the WVE page.
See WVE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
WVE catalysts and pipeline →